<?xml version="1.0" encoding="UTF-8"?>
<ref id="B40">
 <label>40.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Martensson</surname>
    <given-names>J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Holdfeldt</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Sundqvist</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Gabl</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kenakin</surname>
    <given-names>TP</given-names>
   </name>, 
   <name name-style="western">
    <surname>Bjorkman</surname>
    <given-names>L</given-names>
   </name>, 
   <name name-style="western">
    <surname>Forsman</surname>
    <given-names>H</given-names>
   </name>, 
   <name name-style="western">
    <surname>Dahlgren</surname>
    <given-names>C</given-names>
   </name>
  </person-group>
  <year>2018</year>
  <article-title>Neutrophil priming that turns natural FFA2R agonists into potent activators of the superoxide generating NADPH-oxidase</article-title>. 
  <source>J Leukoc Biol</source>
  <volume>104</volume>:
  <fpage>1117</fpage>â€“
  <lpage>1132</lpage>. doi:
  <pub-id pub-id-type="doi">10.1002/JLB.2A0318-130RR</pub-id>.
  <pub-id pub-id-type="pmid">30134499</pub-id>
 </mixed-citation>
</ref>
